Patients' perception, and adherence to treatment with biosimilar adalimumab in psoriasis.

Dadkhahfar, Sahar; Ohadi, Laya; Rahimi, Yasaman; Robati, Reza M; Shekarabi, Marjan; Zargari, Omid; Shahidi-Dadras, Mohammad

Dadkhahfar, Sahar; Ohadi, Laya; Rahimi, Yasaman; Robati, Reza M; Shekarabi, Marjan; Zargari, Omid; Shahidi-Dadras, Mohammad.

Afiliação

Dadkhahfar S; Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ohadi L; Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Rahimi Y; Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Robati RM; Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Shekarabi M; Department of Dermatology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Zargari O; Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Shahidi-Dadras M; Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Dermatol Ther ; 35(2): e15227, 2022 02.

Article em En | MEDLINE | ID: mdl-34822212

Assuntos

Medicamentos Biossimilares; Psoríase; Adalimumab/uso terapêutico; Medicamentos Biossimilares/uso terapêutico; Humanos; Percepção; Psoríase/tratamento farmacológico; Índice de Gravidade de Doença

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / Medicamentos Biossimilares Limite: Humans Idioma: En Revista: Dermatol Ther Assunto da revista: DERMATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Irã País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google